A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
This study is recruiting at 55 US sites in 27 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Graves' Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Immunovant Sciences GmbH
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Site Number - 1036 · Phoenix, AZ
California · 7
- Site Number - 1061 · Huntington Beach, CA
- Site Number - 1001 · Los Angeles, CA
- Site Number - 1047 · Los Angeles, CA
- Site Number - 1062 · Orange, CA
- Site Number - 1046 · Sacramento, CA
- Site Number - 1034 · San Francisco, CA
- Site Number - 1005 · Torrance, CA
Colorado · 1
- Site Number - 1013 · Englewood, CO
Delaware · 1
- Site Number - 1010 · Newark, DE
District of Columbia · 1
- Site Number - 1040 · Washington D.C., DC
Florida · 7
- Site Number - 1029 · Clearwater, FL
- Site Number - 1055 · Jacksonville, FL
- Site Number - 1056 · Jacksonville, FL
- Site Number - 1028 · Miami, FL
- Site Number - 1065 · Miami, FL
- Site Number - 1064 · Ocoee, FL
- Site Number - 1016 · Port Charlotte, FL
Georgia · 2
- Site Number - 1038 · Atlanta, GA
- Site Number - 1053 · Macon, GA
Indiana · 1
- Site Number - 1027 · Indianapolis, IN
Kansas · 1
- Site Number - 1041 · Kansas City, KS
Kentucky · 2
- Site Number - 1045 · Bowling Green, KY
- Site Number - 1054 · Florence, KY
Louisiana · 3
- Site Number - 1063 · Metairie, LA
- Site Number - 1022 · New Orleans, LA
- Site Number - 1048 · Shreveport, LA
Maryland · 1
- Site Number - 1023 · Baltimore, MD
Massachusetts · 1
- Site Number - 1026 · Boston, MA
Michigan · 2
- Site Number - 1018 · Farmington Hills, MI
- Site Number - 1069 · Flint, MI
Minnesota · 1
- Site Number - 1008 · Rochester, MN
Mississippi · 1
- Site Number - 1068 · Gulfport, MS
Nebraska · 1
- Site Number - 1017 · Omaha, NE
Nevada · 1
- Site Number - 1007 · Las Vegas, NV
New York · 1
- Site Number - 1050 · Monroe, NY
North Carolina · 2
- Site Number - 1051 · Asheville, NC
- Site Number - 1060 · Wilmington, NC
Ohio · 1
- Site Number - 1057 · Canton, OH
Oregon · 1
- Site Number - 1003 · Portland, OR
Pennsylvania · 1
- Site Number - 1043 · Pottstown, PA
South Carolina · 1
- Site Number - 1015 · Summerville, SC
Tennessee · 3
- Site Number - 1042 · Chattanooga, TN
- Site Number - 1049 · Nashville, TN
- Site Number - 1066 · Nashville, TN
Texas · 8
- Site Number - 1002 · Austin, TX
- Site Number - 1067 · Bellaire, TX
- Site Number - 1019 · Dallas, TX
- Site Number - 1071 · Houston, TX
- Site Number - 1004 · Mesquite, TX
- Site Number - 1009 · Round Rock, TX
- Site Number - 1014 · San Antonio, TX
- Site Number - 1052 · San Antonio, TX
Utah · 2
- Site Number - 1030 · Salt Lake City, UT
- Site Number - 1070 · Sandy City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.